Statins Do Not Directly Inhibit the Activity of Major Epigenetic Modifying Enzymes
The potential anticancer effects of statins—a widely used class of cholesterol lowering drugs—has generated significant interest, as has the use of epigenetic modifying drugs such as HDAC and DNMT inhibitors. We set out to investigate the effect of statin drugs on epigenetic modifications in multipl...
Main Authors: | Stephanie Bridgeman, Wendy Northrop, Gaewyn Ellison, Thiru Sabapathy, Phillip E. Melton, Philip Newsholme, Cyril D. S. Mamotte |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/4/516 |
Similar Items
-
The HDAC Inhibitor Butyrate Impairs β Cell Function and Activates the Disallowed Gene Hexokinase I
by: Stephanie Bridgeman, et al.
Published: (2021-12-01) -
Beneficial Effects of Statins on Seizures Independent of Their Lipid-Lowering Effect: A Narrative Review
by: Arash Amanlou, et al.
Published: (2023-01-01) -
Pre and post-stroke use of statins improves stroke outcome
by: Majaz Moonis, et al.
Published: (2014-01-01) -
Potential drug interactions with statins:
Estonian register-based study
by: Gavronski Maia, et al.
Published: (2015-04-01) -
Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing
by: Aleksandra Majchrzak-Celińska, et al.
Published: (2021-01-01)